Japan’s Takeda beats Q1 profit estimates on mainstay drugs, dengue vaccine
TOKYO (Reuters) -Japan’s Takeda Pharmaceutical posted first-quarter profit that beat analysts’ estimates, citing solid sales of mainstay drugs and the launch of new products including its dengue fever vaccine. The result marked a better-than-expected start to a rebuilding year for Takeda, as main sellers lose patent protection and it works to wring new winners out of its drug pipeline. Operating profit rose 12% from a year earlier to 168.6 billion […]